Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

AEON

AEON Biopharma Inc.

Jun 14 • 04:00PM ET

1.39

Dollar change +0.03
Percentage change 2.21	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.14	Insider Own	67.35%	Shs Outstand	37.16M	Perf Week	-17.26%
Market Cap	54.38M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	0.00%	Shs Float	12.77M	Perf Month	-12.03%
Income	-141.82M	PEG	-	EPS next Q	-0.19	Inst Own	15.24%	Short Float	1.41%	Perf Quarter	-91.17%
Sales	0.00M	P/S	-	EPS this Y	-1909.52%	Inst Trans	4.33%	Short Ratio	1.68	Perf Half Y	-75.00%
Book/sh	-5.20	P/B	-	EPS next Y	77.11%	ROA	-1150.77%	Short Interest	0.18M	Perf Year	-87.02%
Cash/sh	0.04	P/C	34.86	EPS next 5Y	-	ROE	-27.38%	52W Range	1.26 - 17.17	Perf YTD	-80.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-91.90%	Beta	0.46
Dividend TTM	-	Quick Ratio	0.16	Sales past 5Y	0.00%	Gross Margin	-	52W Low	10.32%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	0.16	EPS Y/Y TTM	-4975.41%	Oper. Margin	0.00%	RSI (14)	33.25	Volatility	9.63% 14.12%
Employees	10	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-16223.20%	Payout	-	Rel Volume	0.23	Prev Close	1.36
Sales Surprise	-	EPS Surprise	-922.58%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	107.22K	Price	1.39
SMA20	-12.19%	SMA50	-59.93%	SMA200	-78.44%	Trades		Volume	24,757	Change	2.21%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-23	Initiated	H.C. Wainwright	Buy	$18

May-29-24 09:35AM	Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround (Zacks) +8.70%
08:00AM	AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan (GlobeNewswire)
May-14-24 04:05PM	AEON Biopharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 09:35AM	AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.21%
08:00AM	AEON Biopharma Provides Update on Development Pipeline (GlobeNewswire)
04:08PM	Loading…
May-03-24 04:08PM	US Equity Markets Close Higher Friday Following Weak Jobs Report (MT Newswires) -49.40%
03:55PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires)
02:37PM	Top Midday Decliners (MT Newswires)
09:05AM	Sector Update: Health Care Stocks Mixed Pre-Bell Friday (MT Newswires)
08:31AM	AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial (MT Newswires)
07:00AM	AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine (GlobeNewswire)
Mar-30-24 10:53PM	CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
Mar-29-24 04:15PM	AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
03:45PM	AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 04:30PM	AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine (GlobeNewswire) -11.60%
04:29PM	Loading…
04:29PM	AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements (GlobeNewswire)
Jan-18-24 04:05PM	AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference (GlobeNewswire)
Dec-12-23 08:00AM	AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine (GlobeNewswire)
Nov-15-23 04:49AM	AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements (GuruFocus.com) +7.61%
Nov-13-23 08:15AM	AEON Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 04:05PM	AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine (GlobeNewswire)
Aug-29-23 08:00AM	AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress® (GlobeNewswire)
Aug-24-23 08:00AM	AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache (GlobeNewswire) +14.91%
Aug-16-23 07:00AM	Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma (GlobeNewswire) +7.06%
Jul-24-23 07:00AM	AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update (GlobeNewswire) -15.13%

AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Strathspey Crown Holdings Grou	10% Owner	Aug 11 '23	Sale	10.00	7,380,394	73,803,940	2,031,773	Aug 14 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AEON

AEON Biopharma Inc.

Upgrade your FINVIZ experience